Estimated Time
1.25 hours
Release Date
Dec 07, 2022
Expiration Date
Jan 02, 2024
Despite the growing list of safe and effective therapies for individuals with T2D, many patients struggle to achieve their glucose target and thus remain at risk for significant comorbidities. Novel unimolecular dual agonists may help address these unmet needs. What role might novel agents play, and how can endocrinologists engage with their patients to make better therapeutic choices? During the session, experts will explain the incretin effect and the roles of GLP-1 and GIP, as well as the potential benefits of agonism of multiple receptors that affect energy homeostasis; they will also interpret the clinical implications of new and emerging data for the first-in-class dual GLP-1 and GIP agonist. Case studies will identify individuals with T2D who may benefit from earlier treatment intensification to improve overall health and delineate practical considerations to help individuals with T2D achieve optimal outcomes.
This taped satellite symposium was derived from the IDF World Diabetes Congress on December 6, 2022.
Speakers
Bernhard Ludvik, MD
Associate Professor of Medicine
Head 1st Medical Department
Landstrasse Clinic
Vienna, Austria
Prof. Bernhard Ludvik, M.D., is Head of the 1st Medical Department with Diabetology, Endocrinology and Nephrology as well of the Karl Landsteiner Institute of Obesity and Metabolic Disorders at the Landstrasse Clinic, Vienna Health Organization, in Vienna, Austria. He is an Associate Professor of Medicine at the Medical University of Vienna. Bernhard Ludvik is a specialist in Internal Medicine and in Endocrinology & Diabetology.
He completed his medical education at the University of Vienna and at the Division of Endocrinology of UCSD in California. Dr. Ludvik served as vice chairman of the Division of Endocrinology at the Medical University of Vienna/General Hospital (AKH) before being appointed Head of the 1st Medical Department of the Landstrasse Clinic.
He obtained numerous awards and was president of the Austrian Diabetes Association and the Austrian Obesity Association. Currently, he is Associate Editor of Obesity Facts and has served on several editorial boards of scientific journals including Diabetologia.
He is author/coauthor of more than 180 papers in peer reviewed journals (h-index 54) and serves as reviewer for various top journals. Dr. Ludvik and his team conduct several studies in the areas of diabetes, metabolism, lipid disorders and kidney diseases in phases 2 and 3 as well as academic studies.
Stefano Del Prato, MD
Professor of Endocrinology
Chief - Section of Diabetes and Metabolic Diseases
Dept of Clinical and Experimental Medicine
University of Pisa
Pisa, Italy
Stefano Del Prato is Professor of Endocrinology and Metabolism at the School of Medicine, University of Pisa and Chief of the Section of Diabetes, University Hospital of Pisa, Italy. He graduated from the University of Padova, Italy and undertook postgraduate specialization in Endocrinology and Internal Medicine. He has been Associate Professor of Medicine at the University of Texas, San Antonio, TX, USA. Professor Del Prato’s main research interests have always been the physiopathology and therapy of type 2 diabetes and insulin resistance. He is a member of many societies and associations including the European Association for the Study of Diabetes (EASD) and the American Diabetes Association. He acts as referee for numerous journals and has served on the Editorial Boards of major scientific journals in the field of diabetes and metabolism. Professor Del Prato is past Vice-President of the EASD, past Chairman of the European Foundation for the Study of Diabetes (EFSD), past President and Honorary President of the Italian Society of Diabetology, and the current President of the European Association for the Study of Diabetes. He also served as Chairman of the Scientific Committee of the World Diabetes Congress in Dubai, UAE, in 2011. He has published over 500 articles in peer-reviewed international journals and has been awarded several honors including the Prize of the Italian Society of Diabetology for outstanding scientific activity, the Honorary Professorship at the Universidad Peruana Cayetano Heredya in Lima and the title of Commander of the Order of the Italian Republic.
Thomas Forst, MD
Johannes Gutenberg University Mainz
Chief Medical Officer, Chairman of the Executive Board
Clinical Research Services
Mannheim, Germany
Professor Thomas Andreas Forst is a certified physician for internal medicine and endocrinology. In 1989, he started his postdoctoral clinical research work at the German Diabetes Research Institute (Leibnitz Institute) at the Heinrich Heine University in Düsseldorf, Germany. In 1999, he completed his academic training in Internal Medicine and Endocrinology at the 3rd Medical Department for Internal Medicine at the Johannes Gutenberg University in Mainz, Germany. Thereafter, he served as a Clinical Research Physician at Eli Lilly Indianapolis and was responsible for several clinical trials with new drugs for the treatment of diabetes mellitus and its vascular complications. In 2001 he took over the position of the CEO and Medical Director of a clinical research unit with special alignment to diabetes and metabolic research (Institute for Clinical Research and Development, Mainz, Germany). In March 2013, Professor Forst joined the Profil Institute, where he established a new clinical research unit in the city of Mainz. Until the end of 2017 he served as the CEO and Director for Medical Science at the Profil Institute Mainz. In January 2018 Professor Forst joined Clinical Research Services Andernach, Germany, where he is now serving as the Chief Medical Officer and Chairman of the Executive Board.
Since 2001 Professor Forst is a teaching professor for Internal Medicine and Endocrinology at the Johannes Gutenberg University in Mainz. Within the last 30 years, Professor Forst was involved in more than 300 clinical trials mainly in the indication of obesity, metabolic diseases, diabetes mellitus, and cardiovascular complications. He is a member of the American, European and German Diabetes Association. Thomas Forst serves as the chairman of the study group Diabetes and Heart and a board member of the neuropathy study group of the German Diabetes Association. Professor Forst has authored or co-authored in excess of three-hundred original articles in peer reviewed National and International Journals. He is a member of several national and international Editorial Boards and an Associate Editor of Diabetes Endocrinology & Diabetes.
Accreditation and Disclosure Information
TARGET AUDIENCE
This CE activity is intended for endocrinologists, diabetologists, and endocrinology fellows who provide care for individuals with T2D.
EDUCATIONAL OBJECTIVES
After completing this CE activity, participants should be better able to:
- Identify individuals with T2D who may benefit from earlier treatment intensification to achieve optimal glucose control and overall health in accordance with current guidelines
- Integrate practical considerations, experience, and SDM techniques to help individuals with T2D achieve and maintain weight loss for optimal outcomes
- Relate the pathophysiology of GLP-1 and GIP to the incretin effect and potential benefits of agonism of multiple receptors that affect energy homeostasis and the MOA of novel therapies
- Interpret the clinical implications of the efficacy and safety data of novel dual agonists for T2D and their potential impact on the treatment paradigm
AGENDA
- Welcome and Introductions
- Addressing Unmet Needs in T2D: Comorbidities, Treatment Intensification, Shared Decision Making for Weight Management
- Demystifying the Evolving Science Behind the Incretin Effect and the Roles of GLP-1 and GIP; Benefits of Agonism of Multiple Receptors that Affect Energy Homeostasis; Mechanism of Action of Unimolecular Dual Agonists
- Clinical Implications of Tirzepatide Efficacy and Safety Data; Identifying Ideal Candidates for Tirzepatide
- Ask Me Anything: Incretins Edition — Final Q&A with Faculty
- Concluding Comments and Key Points
ACCREDITATION, SUPPORT and CREDIT
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc., and Endocrine Society. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ECMEC® Credit
The European Union of Medical Specialists-European Accreditation Council for Continuing Medical Education (UEMS-EACCME®) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit(s)TM into European CME credit (ECMEC®) should contact the UEMS (www.uems.eu).
SUPPORT STATEMENT
This activity is supported by an educational grant by Lilly.
DISCLOSURE & CONFLICT OF INTEREST POLICY
Medical Learning Institute, Inc. and Endocrine Society are committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, we require faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to policy. These disclosures will be provided to learners prior to the start of the CE activity.
FACULTY DISCLOSURES
Planner/Presenter
Bernhard Ludvik, MD
Associate Professor of Medicine
Head, 1st Medical Department
Landstrasse Clinic
Vienna, Austria
Bernhard Ludvik, MD, has a financial interest/relationship or affiliation in the form of:
Research Grant: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Madrigal Pharmaceuticals, Novo Nordisk, Sanofi
Advisory Board/Consultant: Amgen, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi
Speakers’ Bureau: Amgen, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi
Planner/Presenter
Stefano Del Prato, MD
Professor of Endocrinology
Chief – Section of Diabetes and Metabolic Diseases
Dept of Clinical and Experimental Medicine
University of Pisa
Pisa, Italy
Stefano Del Prato, MD, has a financial interest/relationship or affiliation in the form of:
Research Grant: AstraZeneca, Boehringer Ingelheim
Advisory Board/Consultant: Abbott, Applied Therapeutics, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hengrui, Merck Sharp & Dohme, Novo Nordisk, Sandoz, Sanofi, Vertex
Speakers’ Bureau: AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck & Co., Novartis, Novo Nordisk, Sanofi
Planner/Presenter
Thomas Forst, MD
Johannes Gutenberg University Mainz
Chief Medical Officer, Chairman of the Executive Board
Clinical Research Services
Mannheim, Germany
Thomas Forst, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: AstraZeneca, Atrogi, Bayer, Cipla, Eli Lilly, EyeSense, Fortbildungskolleg, Novo Nordisk, Pfizer, Sanofi, reMYND, Roche
Speakers’ Bureau: Amarin, AstraZeneca, Boehringer Ingelheim, Berlin Chemie, Cipla, Daiichi Sankyo, Eli Lilly, Fortbildungskolleg, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi, Santis
All of the relevant financial relationships of individuals for this activity have been mitigated.
PLANNING COMMITTEE AND CONTENT/PEER REVIEWERS
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and Endocrine Society, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute, Inc.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact Mary Vu via email at mvu@mlieducation.org.
ABOUT THIS ACTIVITY
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.
Copyright © 2022 Medical Learning Institute, Inc. All Rights Reserved.